Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Next Previous
X
Search
Trial Profile

A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia; Tumour lysis syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors AbbVie

    • Most Recent Events

    • 31 Jul 2023 Status changed from active, no longer recruiting to completed.
    • 07 Oct 2022 Planned End Date changed from 19 Jul 2023 to 20 Jul 2023.
    • 14 Dec 2021 Results (n=120) assessing the safety and efficacy of obinutuzumab with or without bendamustine as a debulking regimen before venetoclax treatment in the outpatient community setting and the safety and efficacy of subsequent venetoclax plus obinutuzumab treatment after debulking was also evaluated, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top